Investors
Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.
We have 16 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.4 billion (IQVIA, April 2019).
We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.
"We are forging the path to profitable growth and will continue to make the tough decisions needed to grow this business responsibly."
Damian Finio
CFO
Recent News
Teligent, Inc. to Present at Jefferies Global Healthcare Conference in London on Wednesday November 20, 2019
BUENA, N.J. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic phar...
Learn MoreTeligent, Inc. Announces Third Quarter 2019 Results
BUENA, N.J. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...
Learn MoreTeligent, Inc. to Hold Conference Call for Third Quarter 2019 Results on Monday November 4th, 2019
BUENA, N.J. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...
Learn MoreEvents
-
November 20, 2019 at 4:40 PM GMT
Jefferies London Healthcare Conference
Investor Overview
-
Investor Overview
( FY 2018 )Investor Overview 931 KB
Stock Information
Copyright West LLC. Minimum 15 minutes delayed.